Life sciences software & AI news

Daily news on AI, software, and digital tools for pharma, biotech, CROs, and life sciences research labs.

Showing 1000+ results
A minimalist illustration of a nasal spray and a nose, symbolizing PTSD treatment.

Jul 21, 2026

Silo Pharma expects its PTSD nasal-spray study to finish in 60 days

Silo Pharma is on track to complete its study on a nasal spray for PTSD within the next 60 days, alongside advancements in its AI platform aimed at commercial launch.Silo Pharma, a biopharmaceutical company focused on addressing mental health disorders, is progressing with its lead candidate, SPC-15, an intranasal treatment for post-traumatic stress disorder (PTSD). The company is also advancing its AI subsidiary, QwikAgents, which is preparing for a commercial launch anticipated within the next
Stylized upward arrow with circular base symbolizing growth and investment in biotech IPOs.

Jul 21, 2026

Biotech IPO Gains Crush AI Listings With Standout 55% Return

The biotechnology sector is currently outperforming artificial intelligence-related IPOs, showcasing impressive returns that have captured investor attention.According to recent data from Bloomberg, biotech and pharmaceutical companies have achieved a remarkable weighted average return of 55% in their initial public offerings this year. This performance starkly contrasts with the broader US IPO market, which has experienced a weighted average loss of 4.4%, excluding special purpose acquisition c
A minimalist illustration of a pill and a molecule representing the pharmaceutical industry.

Jul 21, 2026

HSBC says pharma remains defensive bet despite AI hype

HSBC's perspective highlights the resilience of the pharmaceutical sector amid the rising influence of AI and economic challenges.Rajesh Kumar, who leads European Life Sciences & Healthcare Equity Research at HSBC, has provided insights into Novartis' recent half-year performance. He emphasizes that the pharmaceutical industry continues to be a stable investment option, even in the face of AI advancements and broader economic uncertainties. Kumar attributes Novartis' success to its strategic pos
A medicine bottle on a pharmacy shelf in dim lighting.

Jul 21, 2026

Polpharma Strengthens Its Position in Central and Eastern Europe – Biofarm, the ...

Polpharma Group has successfully acquired Biofarm, a leading Romanian pharmaceutical company, marking a significant expansion in its Central and Eastern European operations.This acquisition aligns with Polpharma's strategic growth objectives, enhancing its market presence and creating opportunities for improved patient access to essential medications. The CEO of Polpharma, Sebastian Szymanek, emphasized the company's commitment to fostering a robust, multiregional pharmaceutical organization whi
Minimalist illustration of a brain and neurons in a dark palette

Jul 21, 2026

The Institute joins AIRIS Project to build an AI Research Collaborator for Biomedical Science

The AIRIS project aims to revolutionize biomedical research by developing an AI platform that integrates mechanistic models of disease.Current generative AI systems often struggle with accurately modeling diseases, as they primarily focus on statistical correlations rather than the biological mechanisms that drive them. This limitation can lead to unreliable predictions, particularly for diseases with poorly understood mechanisms. The AIRIS initiative, involving 21 partners from Europe, the U.S.
A minimalist representation of an EEG electrode and brain waves.

Jul 21, 2026

Natus expands access to autoSCORE AI analysis through BRAIN QUICK Software

Natus Medical has enhanced its BRAIN QUICK Software by integrating the autoSCORE AI analysis tool, significantly improving access to automated EEG interpretation across Europe and beyond.This update follows the successful launch of autoSCORE with Natus NeuroWorks EEG Software in the U.S. in August 2024, and its subsequent CE mark approval for international markets in March. The incorporation of this AI tool is part of Natus's ongoing commitment to advancing neurodiagnostic technologies, aiming t
Silhouette of a supercomputer with GPUs

Jul 21, 2026

BMS claims pharma's most powerful AI supercomputer. How it stacks up to Lilly's and Roche's.

Bristol Myers Squibb (BMS) has announced the acquisition of an NVIDIA DGX SuperPOD, which it claims is the most powerful and energy-efficient AI supercomputer in life sciences. This announcement comes after Eli Lilly and Roche made their own claims about leading AI supercomputing capabilities within the industry.BMS's new system is an expansion of its existing infrastructure, which has been in operation since 2024. The new setup will integrate eight racks of Vera Rubin NVL72 systems, featuring 5
A preserved woolly mammoth hair sample on a lab table, surrounded by genetic materials.

Jul 21, 2026

Colossal Biosciences Eyes $20B-$30B Valuation in New Funding

Colossal Biosciences is pursuing a significant funding round that could elevate its valuation to between $20 billion and $30 billion, a considerable increase from its previous worth. This ambitious initiative could position the company among the most valuable private biotech entities globally, despite its ongoing quest to revive extinct species like the woolly mammoth and dodo bird.Founded by tech entrepreneur Ben Lamm and geneticist George Church, Colossal is betting on the potential of de-exti
Minimalist illustration of stock growth with an upward arrow and stock chart

Jul 20, 2026

Biotech, AI, and leveraged ETFs soar on corpora...

Recent corporate developments have led to remarkable gains in the biotech and AI sectors, alongside leveraged ETFs. Zhengye Biotechnology experienced an astonishing rise of over 1047%, successfully regaining compliance with Nasdaq regulations after previously receiving a minimum bid price warning. In addition, Advanced Biomed and Axe Compute saw significant increases in their stock prices, attributed to a reverse stock split and their inclusion in the Russell Microcap Index, respectively. Meanwh
A human spleen on a clinical table with an ultrasound probe nearby.

Jul 20, 2026

AI Researcher Receives $745K Award from MA Life Sciences Center

The Massachusetts Life Sciences Center has awarded the SPLEEN-US project $745,000 to enhance AI-driven biomedical research.This funding, part of the MLSC's Bits to Bytes program, aims to develop an extensive open dataset of over 2,000 video scans of spleens, including critical demographic and health-related metadata. The dataset will enable AI algorithms to identify spleen locations on ultrasound images, addressing the challenges posed by the organ's soft texture and location within the body.Ali
A minimalist illustration of a pill and molecular structure representing AI drug discovery.

Jul 20, 2026

AI Drug Discovery

Insilico Medicine has made significant strides in AI drug discovery, as evidenced by its latest advancement into Phase III trials for Rentosertib, a treatment for idiopathic pulmonary fibrosis (IPF).This development showcases the capabilities of Insilico's Pharma.AI platform, which effectively identifies disease targets and designs new drug candidates. The AI-driven approach not only streamlines the drug development process—from target identification to clinical trial optimization—but also highl
A glass vial and research notebook in a dimly lit lab

Jul 20, 2026

Bristol Myers Squibb Expands Partnership with Nvidia | PharmExec

Bristol Myers Squibb is significantly enhancing its AI capabilities through a partnership with Nvidia, aiming to establish a highly advanced AI infrastructure in the life sciences sector.In a strategic move, Bristol Myers Squibb (BMS) is expanding its AI computing framework by integrating Nvidia's DGX SuperPOD, which features the Vera Rubin NVL72 systems. This new infrastructure is touted to deliver up to ten times the performance efficiency per megawatt compared to previous systems, thereby enh